DSGN Q1 2024 Earnings — Design Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DSGNDesign Therapeutics, Inc.

$569M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$143,000

Operating Income

-$14M

Net Income

-$11M

EPS (Diluted)

$-0.20

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$279M

Total Liabilities

$9M

Stockholders' Equity

$270M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$143,000	$0	—
Operating Income	-$14M	-$22M	+33.5%
Net Income	-$11M	-$19M	+42.4%